3.43
price up icon0.00%   0.00
pre-market  Vorhandelsmarkt:  3.70   0.27   +7.87%
loading
Schlusskurs vom Vortag:
$3.43
Offen:
$3.43
24-Stunden-Volumen:
383.57K
Relative Volume:
0.86
Marktkapitalisierung:
$293.54M
Einnahmen:
$351.37M
Nettoeinkommen (Verlust:
$-174.01M
KGV:
-1.657
EPS:
-2.07
Netto-Cashflow:
$-126.94M
1W Leistung:
-3.92%
1M Leistung:
+5.54%
6M Leistung:
+9.94%
1J Leistung:
-9.02%
1-Tages-Spanne:
Value
$3.415
$3.49
1-Wochen-Bereich:
Value
$3.36
$3.74
52-Wochen-Spanne:
Value
$2.455
$4.145

Atea Pharmaceuticals Inc Stock (AVIR) Company Profile

Name
Firmenname
Atea Pharmaceuticals Inc
Name
Telefon
857-204-8109
Name
Adresse
225 FRANKLIN STREET, BOSTON
Name
Mitarbeiter
56
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
AVIR's Discussions on Twitter

Vergleichen Sie AVIR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AVIR
Atea Pharmaceuticals Inc
3.43 305.52M 351.37M -174.01M -126.94M -2.07
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-13 Hochstufung Morgan Stanley Underweight → Equal-Weight
2023-08-10 Herabstufung JP Morgan Neutral → Underweight
2022-01-06 Herabstufung Morgan Stanley Equal-Weight → Underweight
2021-11-18 Herabstufung SVB Leerink Outperform → Mkt Perform
2021-10-20 Herabstufung JP Morgan Overweight → Neutral
2021-10-05 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-11-25 Eingeleitet Evercore ISI Outperform
2020-11-24 Eingeleitet JP Morgan Overweight
2020-11-24 Eingeleitet Morgan Stanley Overweight
2020-11-24 Eingeleitet William Blair Outperform
Alle ansehen

Atea Pharmaceuticals Inc Aktie (AVIR) Neueste Nachrichten

pulisher
Jul 22, 2025

Atea Pharmaceuticals Inc. Stock Analysis and ForecastTurbocharged investment results - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Atea Pharmaceuticals Inc. stockHigh-profit capital plays - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Atea Pharmaceuticals Inc. stock priceRapid profit acceleration - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Atea Pharmaceuticals Inc. a good long term investmentFree Investment Community - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 15, 2025

Why Atea Pharmaceuticals Inc. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Atea Pharmaceuticals Inc. stock price move sharplyFree Stock Portfolio Optimization - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Atea Pharmaceuticals Inc. stock performs during market volatilityFree Stock Movement Tracking - Newser

Jul 15, 2025
pulisher
Jun 29, 2025

Atea Pharmaceuticals announces continued advancement of global Phase 3 HCV program - European AIDS Treatment Group

Jun 29, 2025
pulisher
Jun 26, 2025

Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing - Bain Capital

Jun 26, 2025
pulisher
Jun 24, 2025

New Hepatitis C Treatment Could Slash Therapy Time to 8 Weeks as Global Phase 3 Trial Advances - Stock Titan

Jun 24, 2025
pulisher
Jun 20, 2025

Atea Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 20, 2025
pulisher
Jun 17, 2025

Here's Why We're Not At All Concerned With Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation - Yahoo Finance

Jun 17, 2025
pulisher
Jun 15, 2025

Bank of America Corp DE Boosts Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

Millennium Management LLC Invests $75,000 in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 14, 2025
pulisher
Jun 09, 2025

Squarepoint Ops LLC Buys 35,053 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Two Sigma Investments LP - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Jane Street Group LLC Decreases Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Public Employees Retirement System of Ohio Trims Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Ameriprise Financial Inc. Sells 11,900 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

ProShare Advisors LLC Buys 6,163 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 04, 2025
pulisher
Jun 02, 2025

Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace

Jun 02, 2025
pulisher
May 27, 2025

BNP Paribas Financial Markets Buys New Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 27, 2025
pulisher
May 26, 2025

Northern Trust Corp Boosts Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 26, 2025
pulisher
May 24, 2025

D. E. Shaw & Co. Inc. Purchases 62,505 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 24, 2025
pulisher
May 24, 2025

Wall Street Zen Upgrades Atea Pharmaceuticals (NASDAQ:AVIR) to “Hold” - Defense World

May 24, 2025
pulisher
May 17, 2025

Price T Rowe Associates Inc. MD Purchases 3,882 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 17, 2025
pulisher
May 16, 2025

Q2 EPS Forecast for Atea Pharmaceuticals Reduced by Analyst - Defense World

May 16, 2025
pulisher
May 14, 2025

Dimensional Fund Advisors LP Has $3.27 Million Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 14, 2025
pulisher
May 14, 2025

Transcript : Atea Pharmaceuticals, Inc.Special Call - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Atea Pharmaceuticals Advances HCV Treatment Trials - TipRanks

May 14, 2025
pulisher
May 12, 2025

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 12, 2025

Finanzdaten der Atea Pharmaceuticals Inc-Aktie (AVIR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):